Retatrutide (GLP1R)
For Research Use Only
Injectable
A triple agonist peptide targeting GLP-1, GIP, and glucagon receptors, studied as a next-generation incretin-family research compound. Preclinical work examines multi-receptor metabolic signaling and energy-expenditure pathways in controlled models. Laboratory research areas include: multi-receptor agonism, metabolic rate modeling, and incretin-family pharmacology.
Size: 20mg
$450.00
In stockCheckout opens once payment is connected.
Certificates of analysis
- Batch LL-QC57184296 (published 2026-06-19)
Research guides
- Retatrutide and Triple GLP-1, GIP, and Glucagon Receptor Agonism: What the Published Studies ReportA research-library overview of published findings on retatrutide, a single peptide with agonist activity at the GIP, GLP-1, and glucagon receptors, covering phase 2 and phase 3 randomised trials, meta-analyses, hepatocyte in vitro work, and rodent behavioural pharmacology.
This product is not for human or animal consumption. Misuse of this product is illegal.